Continuous ST-segment monitoring associated with infarct size and left ventricular function in the GUSTO-I trial

American Heart Journal

Volumn 138, Issue 3 I, 1999, Pages 525-532

  Moons, K G M ^a   Klootwijk, P ^a   Meij, S H ^a   Van Es, G A ^a   Baardman, T ^a   Lenderink, T ^a   Van den Brand, M ^a   Habbema, J D F ^a   Grobbee, D E ^a   Simoons, M L ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; HYDROXYBUTYRATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; DISEASE DURATION; DISEASE SEVERITY; ELECTROCARDIOGRAPHY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ST SEGMENT;

EID: 0032840436     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70156-0     Document Type: Article

References (23)

1. Arnold AER, De Jaegere P, Schröder R, et al. Expected infarct size without thrombolysis: a concept that helps to select patients with evolving myocardial infarction for thrombolytic therapy. In: Benefits and risks of thrombolysis for acute myocardial infarction. Rotterdam, The Netherlands: Erasmus University; 1990. Thesis.
2. Gruppo Italiano per lo studio della streptochinasi nel'infarto miocardico (GISSI). Long term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet 1987;1:871-4.
3. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988;2:349-60.
4. Van der Werf F, Arnold AER. Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. Br Med J 1988;297:1374-9.
5. Simoons ML, Vos J, Tijssen JGP, et al. Long term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the Interuniversity Cardiology Institute of The Netherlands. J Am Coll Cardiol 1989; 14:1609-15.
6. GUSTO Investigators. An international trial comparing 4 thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
7. GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-22.
8. Krucoff MW, Green CE, Satler LF, et al. Non-invasive detection of coronary artery patency using continuous ST-segment monitoring. Am J Cardiol 1986;57:916-23.
9. Hogg KJ, Hornung RS, Howie CA, et al. Electrocardiographic prediction of coronary artery patency after thrombolytic treatment in acute myocardial infarction: use of the ST-segment as a non-invasive marker. Br Heart J 1988;60:275-80.
10. Dellborg M, Riha M, Swedberg K. Dynamic QRS-complex and ST-segment monitoring in acute myocardial infarction during recombinant tissue-type plasminogen activator therapy. Am J Cardiol 1991;67:343-9.
11. Hohnloser SH, Zabel M, Kasper W, et al. Assessment of coronary patency after thrombolytic therapy: accurate prediction utilizing the combined analysis of three noninvasive markers. J Am Coll Cardiol 1991;18:44-9.
12. Krucoff MW, Croll MA, Pope JE, et al. Continuously updated 12-lead ST-segment recovery analysis for myocardial infarct artery patency assessment and its correlation with multiple simultaneous early angiographic observation. Am J Cardiol 1993;71:145-51.
13. Klootwijk P, Krucoff MW, Langer A, et al, for the GUSTO ECG-ischemia monitoring substudy. Non-invasive prediction of reperfusion and coronary patency by continuous ST-segment monitoring in the GUSTO trial. Eur Heart J 1996;17:689-98.
14. Dellborg M, Steg PC, Simoons M, et al. Vectorcardiographic monitoring to assess early vessel patency after reperfusion for acute myocardial infarction. Eur Heart J 1995;16:21-9.
15. Delborg M, Riha M, Swedberg K. Dynamic QRS- and ST-segment changes in myocardial infarction monitored by continuous on-line vectorcardiography. J Electrocardiol 1990;23(suppl):11-9.
16. Krucoff MW, Green CL, Langer A, et al. Global utilization of streptokinase and tPA for occluded arteries (GUSTO) ECG-monitoring substudy: study design and technical considerations. J Electrocardiol 1993;26(suppl):249-55.
17. Langer A, Krucoff MW, Klootwij P, et al. Noninvasive assessment of speed and stability of infarct-related artery reperfusion: results of the GUSTO ST-segment monitoring study: global utilization of streptokinase and tissue plasminogen activator for occluded arteries. J Am Coll Cardiol 1995;25:1552-7.
18. Baardman T, Hermens WT, Lenderink T, et al. Differential effects of tissue plasminogen activator and streptokinase on infarct size and on rate of enzyme release: influence of early infarct related artery patency: the GUSTO Enzyme Substudy. Eur Heart J 1996; 17:237-46.
19. Bar FW, Vermeer F, Zwaan De C, et al. Value of admission electrocardiogram in predicting outcome of thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1987;59:6-13.
20. Vermeer F, Simoons ML, Bär FW, et al. Which patients benefit most from early thrombolytic therapy with intracoronary streptokinase? Circulation 1986;74:1379-89.
21. Christian TF, Schwartz RS, Gibbons RJ. Determinants of infarct size in reperfusion therapy for acute myocardial infarction. Circulation 1992;86:81-90.
22. Simoons ML, Arnold AER. Tailored thrombolytic therapy: a perspective. Circulation 1993;88:2556-64.
23. Boersma E, Maas ACP, Deckers JW, et al. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996;348:771-5.